Compare Ascendis Pharma A/S (ASND) vs Best Buy Co Inc (BBY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Best Buy Co Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Best Buy Co Inc trades at $82.11 (market cap $17.45B). The key difference: Ascendis Pharma A/S and Best Buy Co Inc are close in size by market cap, and Best Buy Co Inc pays a 4.64% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | BBY | |
|---|---|---|
Market Cap | $17.74B | $17.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $84.00 |
52-Week Low | $163.32 | $55.52 |
Enterprise Value | $18.11B | $19.83B |
Dividend Yield | — | 4.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Best Buy (BBY) trades at $82.80, up 3.51% with a bullish technical signal. The stock shows strong profitability with a 39.1% ROE and has beaten earnings estimates for three consecutive quarters. Recent news highlights strategic shifts under new CEO Jason Bonfig toward higher-margin services like retail media and marketplace expansion, alongside new product launches such as RGB LED TVs and Meta VR partnerships.
Outlook remains cautiously optimistic with a consensus price target of $82.18. The attractive 4.6% dividend yield and improving cash flow support income investors, but risks include macroeconomic pressures on consumer electronics spending and leadership transitions. Revenue declines since 2022 require monitoring for stabilization under new growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Best Buy Co Inc
With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →
